AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01426750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
Description: The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
Study NCT00888979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotrol Inhaler
Description: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
Study NCT00510601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaneka Liposorber
Description: LDL-apheresis on a bi-weekly basis
Study NCT00568542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoetin beta
Description: 35 I.E. kg body weight subcutaneous once per week for 6 months
Study NCT00568542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 35 I.E. kg body weight placebo to erythropoetin beta
Study NCT04347954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 2%
Description: Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
Study NCT04347954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5%
Description: Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
Study NCT04347954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
Study NCT00716144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily
Study NCT00716144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily
Study NCT03697616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ridge augmentation with sticky bone and GBR
Description: * Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures
Study NCT03890016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 20'Whole Blood ClottingTest (WBCT)
Description: 1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot.
Study NCT03890016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Lee and White (MLW) Method Clotting Time
Description: The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot.
Study NCT03993613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human apotransferrin
Description: Intravenous infusions
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000 mg daily, administered orally
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: 1000 mg daily, administered orally
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000 mg daily, administered orally
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Metformin placebo administered orally. 1000 mg daily
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
Study NCT01511172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Individually adjusted dose, administered orally
Study NCT02728440 — intervention group
Intervention type: DRUG
Intervention: human chorionic gonadotropin, human menopausal gonadotropin
Description: drug for the treatment of male hypogonadism
Study NCT04051255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg
Description: The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
Study NCT02462551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy
Description: A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
Study NCT02762617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravaginal ring (IVR)
Description: The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Study NCT02736071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral Tramadol 100mg 2 hours before the procedure
Study NCT02736071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
Study NCT02736071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
Study NCT04009980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMK2 group
Description: topical administration of OMk2 ophthalmic solution for 36 months three times/day
Study NCT02887768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicardial Infarct Repair with CorMatrix-ECM
Description: CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
Study NCT02887768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting Surgery
Description: All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
Study NCT04009980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: topical administration of ophthalmic placebo solution for 36 months three times/day
Study NCT02862093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
Study NCT02862093 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
Study NCT00633841 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD02
Description: 4 subcutaneous injections of IP in 4-week intervals
Study NCT02427698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cyrolipolysis (CoolSculpting device)
Description: Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
Study NCT02427698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcision
Description: The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin , Levofloxacin and Esomeprazole
Description: Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin , Furazolidone and Esomeprazole
Description: Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Tetracycline , Furazolidone and Esomeprazole
Description: Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin,Levofloxacin and Vonoprazan fumarate
Description: Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin,Furazolidone and Vonoprazan fumarate
Description: Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
Study NCT04810793 — intervention group
Intervention type: DRUG
Intervention: Tetracycline,Furazolidone and Vonoprazan fumarate
Description: Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
Study NCT00751075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS)
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
Study NCT00751075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
Study NCT00751075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
Study NCT00751075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study NCT01104415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules orally three times daily.
Study NCT03608839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml
Description: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
Study NCT03608839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml
Description: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
Study NCT03608839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml
Description: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
Study NCT00903266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy
Description: MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
Study NCT00903266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-Repetition-Therapy
Description: Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
Study NCT02271971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A daily 5.000 IU vitamin D3 capsule during 6 weeks.
Study NCT02271971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily placebo capsule during 6 weeks.
Study NCT01794936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTI Probe
Description: The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
Study NCT04043364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE
Description: Learning, Innovation, Volunteers and Empowerment
Study NCT03213249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intraoperative pocket irrigation with normal saline
Study NCT03213249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Study NCT03213249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
Study NCT03213249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral skin- or nipple-sparing mastectomies
Description: Standard of care
Study NCT03213249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue expander
Description: Standard of care
Study NCT03213249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast implant
Description: * Standard of care~* Either breast implant or autologous flap
Study NCT03213249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous flap
Description: * Standard of care~* Either breast implant or autologous flap
Study NCT03213249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix sling
Description: Standard of care
Study NCT03213249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Study NCT03213249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Study NCT04300426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHIM as solute (10^9 intestinal microbes/ml)
Description: Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Study NCT04300426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACHIM as solute (10^9 intestinal microbes/ml)
Description: Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Study NCT02737878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study NCT00638794 — intervention group
Intervention type: DEVICE
Intervention: Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)
Description: PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
Study NCT01418677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
Study NCT01418677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
Study NCT01418677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
Study NCT01221090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDA
Description: Technological assistance
Study NCT01221090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDSMP
Description: 6-week classes
Study NCT01221090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDA/CDSMP
Description: Combined technology and education
Study NCT00962884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Device (Res-Q-Gard ITD)
Description: Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
Study NCT00962884 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Threshold Device
Description: Breathing through device similar to active device but with the one-way threshold valve removed.
Study NCT00591435 — intervention group
Intervention type: OTHER
Intervention: Comparison of performance of consultants versus residents
Description: Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
Study NCT00127439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manually Assisted Locomotor Training
Description: The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
Study NCT00127439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Locomotor Training
Description: The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.